Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intercell, an Austria-based developer of novel immunomodulatory biologicals, has reported total revenues of EUR12.69m for the second quarter ended 30 June 2011, compared to EUR9.66m for the same period in 2010.
Subscribe to our email newsletter
Intercell has posted a net loss of EUR1.61m for the second quarter of 2011, compared to EUR8.35m for the same period in 2010.
The company’s operating loss was EUR2.42m, compared to EUR8.99m for the same period prior year.
For the six months ended 30 June 2011, the company’s revenues were EUR18.38m, compared to EUR14.41m for the same period in 2010.
Intercell has reported net loss of EUR12.87m for the six months ended 30 June 2011, compared to EUR23.05m for the same period in 2010.
For the six months ended 30 June 2011, the company’s operating loss was EUR12.47m compared to EUR24.01m for the same period prior year.